Funding Details
- Awarder
- Gaingels
- Date Award
- May 24, 2024
- Vertical
- Healthcare and Biotech
- Funding URL
- View Funding Page
- Valuation
-
$33,527,446
Company Info
- Founders
- Neville Sanjana
- Company Description
- A pre-clinical stage biotech that not only develops modifier gene targets that make for more effective cell therapies but also discovers new receptors, called non-MHC restricted T cell receptors, that can safely (in contrast to CARs which are used by most of companies, e.g. Kite/Gilead, Juno/BMS, Novartis) and broadly (in contrast to some companies using MHC-resticted TCRs, e.g. Adaptimmune, Immunocore) target T cells to different cancers but not healthy essential tissue. OverT Bio operates as a biotech company that provide cell therapy for cancers.
- Market
- Healthcare & Wellness
- Coinvestors
- ARTIS Ventures,Alexandria Venture Investments,OMX Ventures,Wing
Links